Health research network TriNetX has partnered with real-world evidence (RWE) data provider Techtrials to add Brazil’s largest integrated real-world dataset to its network.
The strategic collaboration adds to the existing TriNetX healthcare organisation (HCO) members in Brazil and is aimed at adding the real-world dataset in the country to more than 64 million patients.
According to TriNetX, real-world data (RWD) provided by Techtrials represents about 90% of the Brazilian population and provides information for studies involving therapeutic areas such as ultra-rare diseases and oncology.
This RWD comprises information from EMRs, claims, outpatient and hospital procedures, as well as medications, and health outcomes.
Techtrials president and CEO Douglas Andreas Valverde said: “Combining the state-of-the-art TriNetX platform with Techtrials RWD provides an important resource for clinical trial studies.
“We are excited to be partnering with TriNetX to help bring an increased number of research projects to Brazil.”
Partnership with Techtrials augments TriNetX data from several Brazilian HCOs who have already joined the network.
These HCOs include Hospital Moinhos de Vento, Beneficencia Portuguesa De Sao Paulo, Hospital Pequeno Principe, and Instituto Hermes Pardini.
TriNetX CEO Gadi Lachman said: “Brazil is a country that is of significant interest to the pharmaceutical industry.
“The TriNetX network enables the pharmaceutical industry to efficiently collaborate with healthcare organizations, and that will ultimately help bring more clinical trial opportunities to patients in Brazil.”
Last month, TriNetX launched a Covid-19 Rapid Response Network to enable the pharmaceutical community to design clinical trials using RWD.
In March this year, TriNetX partnered with Medical Data Vision (MDV), a provider of a health claims and administrative data from more than 400 acute hospitals in Japan.